|
| Status |
Public on Apr 27, 2017 |
| Title |
PAX3-FOXO1 establishes myogenic super enhancers [RMS Chip-seq] |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
The fusion transcription factor PAX3-FOXO1 drives oncogenesis in a subset of rhabdomyosarcomas, however the mechanisms by which it remodels chromatin are unknown. We find PAX3-FOXO1 reprograms the cis-regulatory landscape by inducing super enhancers (SEs), in collaboration with master transcription factors MYOG, MYOD and MYCN. This myogenic SE circuitry is consistent across cell lines and primary tumors. Deregulation of PAX3-FOXO1 itself occurs by translocation-induced chromatin loops bringing the PAX3 promoter under the control of FOXO1 enhancers. Protein targets induced by, or bound to, PAX3-FOXO1 occupied SEs, were selectively sensitive to small molecule inhibition. PAX3-FOXO1 co-binds BRD4 at SEs, and BET bromodomains are required for PAX3-FOXO1-dependent transcription and cancer cell growth.
|
| |
|
| Overall design |
Genome-wide profiles for histone marks, DNase hypersensitivity, transcription factors, coactivators and architectural proteins in Rhabdomyosarcoma (RMS) cell lines and tissues
|
| |
|
| Contributor(s) |
Gryder BE, Wen X |
| Citation(s) |
28446439, 32744500 |
| Submission date |
Jun 26, 2016 |
| Last update date |
May 06, 2021 |
| Contact name |
Javed Khan |
| E-mail(s) |
khanjav@mail.nih.gov
|
| Phone |
2407606135
|
| Organization name |
NCI, NIH
|
| Department |
Genetics Branch
|
| Lab |
Javed Khan
|
| Street address |
37 Convent Dr.
|
| City |
Bethesda |
| State/province |
MD |
| ZIP/Postal code |
20892 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (54)
|
|
| This SubSeries is part of SuperSeries: |
| GSE83728 |
Epigenetic Lanscape and BRD4 Transcriptional Dependency of PAX3-FOXO1 Driven Rhabdomyosarcoma |
|
| Relations |
| BioProject |
PRJNA326877 |
| SRA |
SRP077229 |
Less...
More...